3 years ago

Nucleome Therapeutics Secures £37.5 Million to Decode the Human Genome for New Medicines

  • Oxford-based biotech startup Nucleome Therapeutics has raised £37.5 million in a Series A funding round

  • The company uses machine learning to decode the human genome and discover new medicines, particularly for autoimmune diseases

  • The investment will support Nucleome's research and development efforts, including advancing its target and drug discovery programs.

      • ProblemHealthcare

      "Current methods for discovering new medicines are inefficient and often fail to target the root cause of diseases, particularly autoimmune diseases. The majority of disease-associated genetic changes occur in a 'dark area' of the human genome that is poorly understood, making it difficult to identify new drug targets."

      Solution

      "Nucleome Therapeutics has developed a platform technology that uses machine learning to decode the human genome, including the 'dark area'. This allows them to identify new drug targets for autoimmune diseases and other conditions. By understanding the genetic basis of these diseases, they can develop more effective and targeted treatments."

      Covered on